Cargando…

A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats

BACKGROUND: Oclacitinib is a Janus kinase (JAK) 1 enzyme inhibitor and blocks JAK1-dependent cytokines and is used to control pruritus. Studies available in cats are very limited and as there is a potential role for oclacitinib in the control of pruritus in this specie, the aim of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopes, Natália Lôres, Campos, Diefrey Ribeiro, Machado, Marília Alves, Alves, Mariana Silva Revoredo, de Souza, Manuela Silva Gomes, da Veiga, Cristiano Chaves Pessoa, Merlo, Alexandre, Scott, Fábio Barbour, Fernandes, Julio Israel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506962/
https://www.ncbi.nlm.nih.gov/pubmed/31068210
http://dx.doi.org/10.1186/s12917-019-1893-x
_version_ 1783416943818047488
author Lopes, Natália Lôres
Campos, Diefrey Ribeiro
Machado, Marília Alves
Alves, Mariana Silva Revoredo
de Souza, Manuela Silva Gomes
da Veiga, Cristiano Chaves Pessoa
Merlo, Alexandre
Scott, Fábio Barbour
Fernandes, Julio Israel
author_facet Lopes, Natália Lôres
Campos, Diefrey Ribeiro
Machado, Marília Alves
Alves, Mariana Silva Revoredo
de Souza, Manuela Silva Gomes
da Veiga, Cristiano Chaves Pessoa
Merlo, Alexandre
Scott, Fábio Barbour
Fernandes, Julio Israel
author_sort Lopes, Natália Lôres
collection PubMed
description BACKGROUND: Oclacitinib is a Janus kinase (JAK) 1 enzyme inhibitor and blocks JAK1-dependent cytokines and is used to control pruritus. Studies available in cats are very limited and as there is a potential role for oclacitinib in the control of pruritus in this specie, the aim of this study was to evaluate the safety and clinical effects of oral oclacitinib maleate in healthy cats. RESULTS: Thirty mixed-breed cats weighing from 2.1 to 5.3 kg each were randomly allocated to three treatment groups of 10 animals each. Cats in two groups received oclacitinib at 1 mg/kg or 2 mg/kg q 12 h orally for 28 days. Cats in the third group were given placebo tablets (cornstarch) q 12 h orally for 28 days. Oclacitinib maleate was well tolerated during the study and few adverse events were observed in treated cats. Clinical signs of toxicity were not observed in any animals treated at 1 mg/kg. Gastrointestinal clinical signs observed in the 2 mg/kg group included vomiting in two of the 10 cats and soft stools in two cats. One cat treated with placebo also exhibited soft stools. No significant differences were observed between the groups for hematologic analyses performed during the study. There was a slight increase in neutrophils and monocytes and a decrease in eosinophil mean counts in treated cats. Mean renal and liver enzymes remained normal throughout the entire study. A small, but significant increase in fructosamine levels was observed for both treated groups compared with placebo; however, values remained within the normal reference range. There were no significant difference between treated groups and the placebo group for urine specific gravity, pH, or urine protein to creatinine ratio mean values. CONCLUSIONS: Oclacitinib maleate was well tolerated by cats at 1 mg/kg and 2 mg/kg and appeared to be safe for this species when administered orally twice daily for 28 days. More studies would be needed to demonstrate if oclacitinib maleate may be a suitable alternative to treat pruritic cats.
format Online
Article
Text
id pubmed-6506962
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65069622019-05-13 A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats Lopes, Natália Lôres Campos, Diefrey Ribeiro Machado, Marília Alves Alves, Mariana Silva Revoredo de Souza, Manuela Silva Gomes da Veiga, Cristiano Chaves Pessoa Merlo, Alexandre Scott, Fábio Barbour Fernandes, Julio Israel BMC Vet Res Research Article BACKGROUND: Oclacitinib is a Janus kinase (JAK) 1 enzyme inhibitor and blocks JAK1-dependent cytokines and is used to control pruritus. Studies available in cats are very limited and as there is a potential role for oclacitinib in the control of pruritus in this specie, the aim of this study was to evaluate the safety and clinical effects of oral oclacitinib maleate in healthy cats. RESULTS: Thirty mixed-breed cats weighing from 2.1 to 5.3 kg each were randomly allocated to three treatment groups of 10 animals each. Cats in two groups received oclacitinib at 1 mg/kg or 2 mg/kg q 12 h orally for 28 days. Cats in the third group were given placebo tablets (cornstarch) q 12 h orally for 28 days. Oclacitinib maleate was well tolerated during the study and few adverse events were observed in treated cats. Clinical signs of toxicity were not observed in any animals treated at 1 mg/kg. Gastrointestinal clinical signs observed in the 2 mg/kg group included vomiting in two of the 10 cats and soft stools in two cats. One cat treated with placebo also exhibited soft stools. No significant differences were observed between the groups for hematologic analyses performed during the study. There was a slight increase in neutrophils and monocytes and a decrease in eosinophil mean counts in treated cats. Mean renal and liver enzymes remained normal throughout the entire study. A small, but significant increase in fructosamine levels was observed for both treated groups compared with placebo; however, values remained within the normal reference range. There were no significant difference between treated groups and the placebo group for urine specific gravity, pH, or urine protein to creatinine ratio mean values. CONCLUSIONS: Oclacitinib maleate was well tolerated by cats at 1 mg/kg and 2 mg/kg and appeared to be safe for this species when administered orally twice daily for 28 days. More studies would be needed to demonstrate if oclacitinib maleate may be a suitable alternative to treat pruritic cats. BioMed Central 2019-05-08 /pmc/articles/PMC6506962/ /pubmed/31068210 http://dx.doi.org/10.1186/s12917-019-1893-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Lopes, Natália Lôres
Campos, Diefrey Ribeiro
Machado, Marília Alves
Alves, Mariana Silva Revoredo
de Souza, Manuela Silva Gomes
da Veiga, Cristiano Chaves Pessoa
Merlo, Alexandre
Scott, Fábio Barbour
Fernandes, Julio Israel
A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats
title A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats
title_full A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats
title_fullStr A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats
title_full_unstemmed A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats
title_short A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats
title_sort blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506962/
https://www.ncbi.nlm.nih.gov/pubmed/31068210
http://dx.doi.org/10.1186/s12917-019-1893-x
work_keys_str_mv AT lopesnatalialores ablindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats
AT camposdiefreyribeiro ablindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats
AT machadomariliaalves ablindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats
AT alvesmarianasilvarevoredo ablindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats
AT desouzamanuelasilvagomes ablindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats
AT daveigacristianochavespessoa ablindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats
AT merloalexandre ablindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats
AT scottfabiobarbour ablindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats
AT fernandesjulioisrael ablindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats
AT lopesnatalialores blindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats
AT camposdiefreyribeiro blindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats
AT machadomariliaalves blindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats
AT alvesmarianasilvarevoredo blindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats
AT desouzamanuelasilvagomes blindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats
AT daveigacristianochavespessoa blindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats
AT merloalexandre blindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats
AT scottfabiobarbour blindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats
AT fernandesjulioisrael blindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats